About Alnara Pharmaceuticals
Alnara Pharmaceuticals is a Healthcare company based in Cambridge (United States) founded in 2008, and was acquired by Lilly in July 2010. Protein therapeutics for metabolic diseases are developed orally. Alnara Pharmaceuticals has raised $55 million across 2 funding rounds from investors including Lilly, Bessemer Venture Partners and Frazier Healthcare Partners. Its focus areas include Life Sciences, Metabolic Diseases and Drugs. Its legal entity is Alnara Pharmaceuticals, Inc. Its competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Alnara Pharmaceuticals was established in 2008 in Cambridge, United States, within the biotechnology sector. Novel protein therapeutics are developed for metabolic diseases, with operations centered on oral delivery to the gastrointestinal tract to bypass bloodstream absorption. The lead product, liprotamase, addresses cystic fibrosis and was licensed worldwide from the Cystic Fibrosis Foundation for development and commercialization. Acquisition by Eli Lilly took place in 2010 for 380 million USD.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website alnara.com
- Social LinkedIn
- Acquired by Lilly (Jul 2010)
- Legal Name Alnara Pharmaceuticals, Inc
Funding Insights of Alnara Pharmaceuticals
Alnara Pharmaceuticals has successfully raised a total of $55M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $35 million completed in January 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $55M
- Total Rounds 2
- Last Round Series B — $35M
- First Round $20M
(Oct 2008)
- Investors Count 4
All 2 funding rounds of Alnara Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2010 | $35M | Series B | – | MPM Capital | |
| Oct 2008 | $20M | Series A | – | – |
5 investors in total: 5 institutional.
Investors in Alnara Pharmaceuticals
Alnara Pharmaceuticals has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Bessemer Venture Partners and Frazier Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments and support for entrepreneurs in technology and innovation sectors. | 1911 | bvp.com | Redwood City, United States | |
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States |
Investor details for Alnara Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Alnara Pharmaceuticals
4 dated milestones of Alnara Pharmaceuticals across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Alnara Pharmaceuticals is founded.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Series B, of $35.0M.
- Exit Acquired by Lilly.
Competitors of Alnara Pharmaceuticals
Alnara Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. |
Detailed competitors of Alnara Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Alnara Pharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alnara Pharmaceuticals
Complete news archive for Alnara Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alnara Pharmaceuticals
Alnara Pharmaceuticals was founded in 2008.
Alnara Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Alnara Pharmaceuticals is a funded company, having raised a total of $55M across 2 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Oct 2008.
Alnara Pharmaceuticals was established in 2008 in Cambridge, United States, within the biotechnology sector. Novel protein therapeutics are developed for metabolic diseases, with operations centered on oral delivery to the gastrointestinal tract to bypass bloodstream absorption. The lead product, liprotamase, addresses cystic fibrosis and was licensed worldwide from the Cystic Fibrosis Foundation for development and commercialization. Acquisition by Eli Lilly took place in 2010 for 380 million USD.
Alnara Pharmaceuticals's top competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.
Alnara Pharmaceuticals has 5 investors. Key investors include Lilly, Bessemer Venture Partners, Frazier Healthcare Partners, Turmeric Acquisition Corp, and Third Rock Ventures.
Alnara Pharmaceuticals operates through Alnara Pharmaceuticals, Inc.
Yes. Alnara Pharmaceuticals was acquired by Lilly in July 2010.